Avania Names MedTech Industry Veteran, Todd M. Pope, New Chairman of the Board
Avania, a leading, global medical technology contract research organization (CRO), today announced its appointment of Todd M. Pope as the new chairman of the board of directors. Todd brings 30 years of technology, medical device, and leadership experience across large cap and startup MedTech and was named to TIME Magazine’s 2018 list of 50 Most Influential People in Healthcare. Having spent the last 20 years in CEO roles in both private and public companies, he also currently serves as the chairman of the board of directors of AdvaMed ACCEL, the division within AdvaMed dedicated to addressing the unique needs of small and startup medical technology manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005199/en/
Avania Names Todd M. Pope New Chairman of the Board (Photo: Business Wire)
“I am very pleased to take on this role at such a dynamic time and support Avania on its growth journey,” said Pope. “After a rewarding career leading companies in the MedTech industry, I am motivated by the opportunity to work alongside the senior management team to execute on Avania’s transformational business strategy.”
Todd’s previous roles included global president of Johnson & Johnson Cordis, president and CEO of TransEnterix, as well as other senior executive positions within the MedTech space. Todd is currently director of the boards of Distalmotion and Humacyte, and a partner at Revival Healthcare Capital.
“Todd’s long history of leadership, coupled with his deep operating and commercial experience in the MedTech space makes him an ideal person for this role,” said Sapna Hornyak, president and CEO of Avania. “I look forward to working closely with Todd to ensure Avania continues to make a positive impact for all stakeholders, including Avania’s customers, our people, and the MedTech community. The senior management team along with the board of directors are excited about the future and look forward to bringing Avania to the next new phase with our new chairman.”
“We are very excited to be working with Todd,” added Edouard Pillot, managing partner, and Enrico Grasso, partner of Astorg Mid-Cap, which has majority interest in Avania. “He brings a wealth of MedTech industry experience and relationships that will provide invaluable connections with customers as well as insights into their evolving needs, and how Avania can best serve them. Todd’s leadership experience, with small and large businesses, will also support Avania as it grows and scales.”
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005199/en/
Contact information
Lindsey Langemeier
SCORR Marketing
+1 402-405-4269
lindsey@scorrmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 15:00:00 EET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 15:00:00 EET | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes will be used to refinance certain indebtedness in connection with CWL11 and CWL13 (including the
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 15:00:00 EET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 14:57:00 EET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 14:30:00 EET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom